Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary efficacy endpoint demonstrated that the median duration of SOM from baseline through short-term follow-up period was 0.0 days in EC-18, an immunomodulator, group versus 13.5 days in the placebo group (100% reduction).
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary efficacy endpoint demonstrated that the median duration of SOM (defined as WHO Grades 3 or 4) from baseline through short-term follow-up period (STFU) was 0.0 days in the EC-18 group versus 13.5 days in the placebo group (100% reduction).
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2022
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase II trial of EC-18 is a synthetic monoacetyldiaglyceride treat oral mucositis in individuals with concomitant chemo-irradiation for mouth, hypopharynx, oropharynx, and nasopharynx cancers.
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EC-18 is in clinical development in Phase 2 clinical trials in chemoradiation-induced oral mucositis and COVID-19. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021
Details : At Biotech Showcase 2021, the company will provide a corporate update for its clinical programs, specifically its Phase 2 COVID-19 study and its Phase 2 clinical trial of EC-18 in Chemoradiation-induced Oral Mucositis, which will report results in the fi...
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster titled "First in-class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histologic features of nonalcoholic steatohepatitis (NASH) in vitro and in vivo" will be presented at the EASL Co...
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster titled Titled "TLR Signaling Inhibition with Mosedipimod" will be presented at the conference. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.
Product Name : EC-18
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable